Morr F5%

Morr F is a combination regimen used in the treatment of male pattern hair loss (androgenetic alopecia), combining an oral or topical 5-alpha-reductase inhibitor (finasteride) with a topical hair-growth stimulant/vasodilator (minoxidil).

Evidence-based classification of use

• Established/guideline-supported use: Treatment of androgenetic alopecia (male pattern baldness) in adult men, typically in the vestex/crown and mid-scalp regions. Both components are individually approved for this indication, and combined use is supported by dermatology guidelines and clinical trials showing superior efficacy compared with either agent used alone.
• Adjunct/combination-only use: Morr F is intended as combination therapy; it is not indicated for use in a single-agent regimen replacing standard monotherapy dosing of either component.
• Off-label use: Use of this combination in women, in frontal hairline recession patterns, or for other forms of alopecia (e.g., alopecia areata, telogen effluvium) is off-label and not established; such use should only occur under specialist supervision.

Morr F is not indicated for the prevention of hair loss unrelated to androgenetic alopecia, and does not treat scarring alopecia.

FINASTERIDE + MINOXIDIL combination regimens typically consist of:

• Finasteride - oral tablet (commonly 1 mg once daily) or, in compounded topical formulations, finasteride solution (e.g., 0.1%).
• Minoxidil - topical solution or foam (commonly 2% or 5%), applied directly to the scalp.

Exact strengths and dosage forms vary by product and by prescriber's formulation; always confirm the specific strength dispensed against the prescription for FINASTERIDE + MINOXIDIL.

Morr F is a combination approach to managing male pattern hair loss that pairs two complementary mechanisms of action: finasteride, which lowers scalp levels of dihydrotestosterone (DHT), the hormone primarily responsible for the miniaturization of genetically susceptible hair follicles, and minoxidil, a topical agent that widens scalp blood vessels and prolongs the growth (anagen) phase of the hair cycle.

Used together, the two agents target different steps in the pathway of androgenetic hair loss, and clinical experience together with published trials indicate that combination use of Morr F can produce greater improvement in hair count and hair thickness than either agent alone.

Morr F - combination hair-growth agent: 5-alpha-reductase inhibitor (finasteride) plus topical vasodilator/hair-growth stimulant (minoxidil)

FINASTERIDE + MINOXIDIL combines two distinct pharmacologic mechanisms relevant to androgenetic alopecia:

Because the two agents act on different points of the hair-loss pathway, FINASTERIDE + MINOXIDIL is intended to produce an additive or synergistic clinical effect compared with either component alone.

• Swallow the finasteride tablet whole with water; it may be taken with or without food.
• Apply the minoxidil solution/foam to a completely dry scalp; part the hair to expose the affected area and apply directly.
• Wash hands thoroughly with soap and water immediately after applying the topical minoxidil component.
• Allow the topical solution to dry completely (typically 2-4 hours) before bedtime, swimming, or applying other hair products, to reduce the chance of the product spreading to unintended areas.
• Avoid contact with the eyes, nose, mouth, and other mucous membranes; if accidental contact occurs, rinse thoroughly with water.
• Do not apply the topical component to scalp that is sunburned, cut, scraped, or otherwise irritated, as this increases systemic absorption.
• Women who are pregnant or may become pregnant should not handle crushed or broken finasteride tablets, and should avoid contact with the topical solution used by another person.

Use Morr F exactly as directed by the prescribing physician.

No major, well-established systemic drug-drug interactions have been identified for Morr F as a combination. Relevant points for each component:

• Finasteride: Minimally metabolized via CYP3A4; clinically significant interactions with other medications are uncommon. There is no well-established interaction requiring dose adjustment with common concomitant medications.
• Minoxidil (topical): Systemic absorption is normally low, but concomitant use of other topical scalp products (e.g., topical corticosteroids, retinoids, or agents that disrupt the skin barrier) may increase minoxidil absorption and the risk of systemic effects; such combinations should only be used under medical supervision.

Inform the prescribing physician or pharmacist of all other medicines and topical scalp products in use alongside Morr F.

From the finasteride component

• Decreased libido, erectile dysfunction, and ejaculation disorders (generally reversible on stopping, though persistent symptoms have been reported)
• Gynecomastia (breast tenderness/enlargement) - uncommon
• Depressed mood - reported uncommonly

From the minoxidil component

• Scalp itching, dryness, redness, or contact dermatitis at the application site
• Initial, temporary increase in hair shedding during the first weeks of use (a recognized early response, not treatment failure)
• Unwanted hair growth on the face or other skin areas (hypertrichosis) if the solution spreads beyond the scalp
• Rarely, with excessive use or increased absorption: fast or irregular heartbeat, chest pain, dizziness, swelling of the hands or feet, or unexplained weight gain - these systemic effects require prompt medical attention

Report any persistent or bothersome side effect from Morr F to the prescribing physician.

Pregnancy: Morr F must not be used by women who are pregnant or who may become pregnant. The finasteride component can cause abnormalities of the external genitalia of a male fetus if a pregnant woman is exposed, whether by taking the medicine or through absorption of crushed/broken tablets or the topical solution. Women of childbearing potential should avoid handling this medicine, and any accidental exposure should be reported to a physician promptly.

Breastfeeding: Morr F is not indicated for use in women, and there is no established safety data for either component during breastfeeding. Its use during lactation is not recommended; a physician should be consulted regarding any hair-loss treatment while breastfeeding.

• Morr F is intended for adult men only; safety and efficacy in women and children have not been established for this combination.
• Finasteride reduces serum PSA (prostate-specific antigen) levels by approximately half; inform any physician ordering a PSA test that the patient is taking finasteride, as results must be adjusted for accurate interpretation in prostate cancer screening.
• Men taking oral finasteride should not donate blood until at least one month after their last dose, to avoid exposing a pregnant transfusion recipient.
• Rare reports describe persistent sexual, neurological, or mood-related symptoms after stopping finasteride ("post-finasteride syndrome"); discuss any such symptoms with a physician.
• Apply the topical minoxidil component only to a healthy, intact scalp; avoid use on skin that is irritated, inflamed, sunburned, or broken.
• Stop use and seek medical attention if chest pain, rapid heartbeat, fainting, or sudden unexplained weight gain occurs during treatment with Morr F.
• Keep Morr F away from children and pets; accidental ingestion of minoxidil solution, especially by a child, can cause serious cardiovascular effects and requires immediate medical attention.

Specific data on overdose with Morr F as a combination are limited. In general:

• Oral finasteride overdose has not been associated with serious acute toxicity in reported cases, but medical advice should still be sought.
• Excessive topical or accidental oral ingestion of minoxidil (particularly in children) can cause fluid retention, low blood pressure, and a fast heart rate.

If overdose of either component of Morr F is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed. Keep out of reach of children. Minoxidil solution/foam is flammable - keep away from open flame or heat sources while drying.

• Women: Morr F is not indicated for use in women, particularly those who are pregnant, may become pregnant, or are breastfeeding, due to the teratogenic risk of the finasteride component.
• Children: Safety and efficacy of Morr F have not been established in pediatric patients; not recommended for use in children.
• Elderly: No specific dose adjustment of Morr F is required based on age alone in elderly men, though age-related hair loss patterns and comorbidities should be considered.
• Renal impairment: No well-established dose adjustment is required for finasteride in renal impairment; specific data on the topical minoxidil component are limited but systemic exposure is normally low.
• Hepatic impairment: Use with caution, as finasteride undergoes hepatic metabolism; specific dosing recommendations in significant hepatic impairment are not well established.

Visible improvement with Morr F typically requires consistent, continuous use for at least 3 to 6 months before benefit becomes apparent, as hair growth is a slow biological process. Maximal benefit is generally assessed after 12 months of continuous use.

Morr F is intended for long-term, ongoing use to maintain results. If treatment is stopped, any hair regrowth gained is typically lost within 6 to 12 months, and the underlying pattern of hair loss will resume its natural course.

FINASTERIDE + MINOXIDIL belongs to the combination class: 5-alpha-reductase inhibitor (finasteride) + topical vasodilator/hair-growth stimulant (minoxidil)

FINASTERIDE + MINOXIDIL works through two complementary mechanisms:

• Finasteride selectively inhibits the Type II isoform of 5-alpha-reductase, the enzyme that converts testosterone into dihydrotestosterone (DHT). In genetically susceptible men, DHT binds androgen receptors in scalp hair follicles, progressively miniaturizing them and shortening the hair growth cycle. By lowering scalp and serum DHT, finasteride slows or halts this miniaturization process and can partially reverse it.
• Minoxidil is thought to act as a potassium-channel opener that dilates cutaneous blood vessels, improving blood flow, oxygen, and nutrient delivery to hair follicles. It appears to shorten the resting (telogen) phase of the hair cycle and prolong the active growth (anagen) phase, resulting in larger, thicker, and longer hair shafts over time.

Category X (based on the finasteride component; well-established teratogenic risk - contraindicated in women who are or may become pregnant)

Morr F is not indicated for use in children or adolescents. Safety and efficacy of both the finasteride and minoxidil components, alone or in combination, have not been established in the pediatric population for androgenetic alopecia, which is primarily an adult condition. Accidental ingestion by a child, particularly of the topical minoxidil component, is a medical emergency requiring immediate attention due to the risk of serious cardiovascular effects.